This internal Theranos board of directors deck, dated December 7, 2010, was produced as a court exhibit. It opens with a cover slide and an agenda running from a light breakfast through administrative items, products, commercial, organization, legal, finance and a closing discussion. The administrative section covers approvals and director matters, including warrant approval, minutes, a director search process and compensation review. The 2010 goals recap sets targets for launching Theranos Systems 4.0, reaching volume capacity and signing commercial deals. The products section pairs a row of instrument photographs with a validation grid of charts for technologies such as centrifugation, nucleic acid amplification, cytometry, colorimetry, ELISA and robotics. The commercial section presents a 2011 quarterly plan and lists retail, pharmaceutical and provider partners by logo text. The organization slide describes restructuring and hiring targets, the legal slide lists a patent portfolio table with codes and status, and the finance slide covers real estate and financing items. Built largely from dense bullet text and tables in a consistent green template, each slide is marked confidential in its footer.
Full text of the slides (22 slides)
Every slide's words and a description of its charts and images, so the deck can be searched and rebuilt. Also available as Markdown.
Slide 1
15046
Message
From: Elizabeth Holmes [/O=THERANOS ORGANIZATION/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS/CN=EHOLMES]
Sent: 12/7/2010 2:11:01 PM
To: Sunny Balwani [[email protected]]
Elizabeth Holmes
President and CEO
Theranos, Inc.
Tel: 650.470.6111
Fax: 650.838.9804
=========================================
PRIVILEGED AND CONFIDENTIAL COMMUNICATION
IMPORTANT -- This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.
Theranos, Inc., 3200 Hillview Avenue, Palo Alto, CA, 94304
650-838-9292 www.theranos.com
=========================================
FOIA Confidential Treatment Requested by Theranos
TS-0967741
Visuals: A full-page scan of a printed email message on white paper, with black text and one thick black horizontal rule under the word Message. No photographs, charts, logos or icons. The scan is full-bleed across the whole slide with slight grey scanning texture and no framing, cropping or overlay.
Slide 2
File Produced in Native Format
FOIA Confidential Treatment Requested by Theranos
TS-0967742
Slide 3
Meeting of the Board of Directors
December 7, 2010
8:15 a.m. – 11:45 a.m.
Theranos, Inc.
This presentation and its contents are Theranos proprietary and confidential
Visuals: Logo: the theranos corporate logo at top left (image 232 by 63 pixels, placed at x 2.7%, y 3.5%, w 24.2%, h 8.8%). It shows a green faceted diamond mark with a white four-point cross-shaped centre, a grey italic lowercase wordmark 'theranos' to its right, and a small grey italic tagline 'redefining healthcare' beneath the wordmark, left-aligned to the wordmark. No photographs, charts, tables or other illustrations.
Slide 4
theranos
redefining healthcare
Agenda
Light breakfast
8:15 – 8:30
Administrative
8:30 – 9:00
Products
9:00 – 9:30
Commercial
9:30 – 10:10
Organization
10:10 – 10:40
Legal
10:40 – 10:55
Finance
10:55 – 11:15
Discussion and close of
meeting
11:15 – 11:45
Theranos Confidential
2
Visuals: A table with two columns and eight rows and no header row. Column 1 holds activity names and column 2 holds time ranges. Row 1: Light breakfast | 8:15 – 8:30. Row 2: Administrative | 8:30 – 9:00. Row 3: Products | 9:00 – 9:30. Row 4: Commercial | 9:30 – 10:10. Row 5: Organization | 10:10 – 10:40. Row 6: Legal | 10:40 – 10:55. Row 7: Finance | 10:55 – 11:15. Row 8: Discussion and close of meeting | 11:15 – 11:45. Cell fills alternate in tints of teal: row 1 #BBE0E3, rows 2, 3, 6 and 8 #E7F3F4 (row 8 is taller at 10.4%), rows 4, 5 and 7 #F3F9FA, separated by thin white gutters. The theranos logo is a raster image of 232 by 63 pixels: a green (#00875A-like) faceted diamond emblem at left, with the italic grey wordmark 'theranos' in grey (#6D6E71-like) and the small grey tagline 'redefining healthcare' beneath it. No photographs, charts or other graphics.
Slide 5
theranos / redefining healthcare / Administrative / Approval of updated BCBSVP warrant / Approval of prior minutes / • Meeting of the Board of Directors – Tuesday, August 10th, 2010 / Approval of Channing Robertson agreement structure / Acceptance of Pete Thomas resignation / Approval of Pete Thomas strategic advisory agreement terms / Theranos Confidential / 3
Visuals: One raster image: the Theranos logo at top left, box x 2.7%, y 3.5%, 24.2% wide by 8.8% high (232 by 63 pixels). It shows a green faceted diamond-shaped emblem with a white four-point cross-cut centre, to the left of the lowercase grey italic wordmark 'theranos' and the small grey italic tagline 'redefining healthcare' beneath it. The emblem's dominant colours are green gradients (#008851 to lighter mint) with grey #6A737B wordmark text. The logo is not cropped and has no overlay. No other visual elements are present.
Slide 6
Administrative
Theranos logo: theranos redefining healthcare
Approval of new director search process
Review of new candidate matrix
Review of existing employee stock compensation matrix and new hire
salary ranges
Clarification to schedule for payment of cash based compensation for
directors
Review of director compensation matrix
Theranos Confidential
4
Visuals: One logo: the theranos logo in the top-left corner, consisting of a green faceted diamond/rhombus emblem with a white inner cross-shaped cutout and gradient shading from light to dark green on the left, followed by the lowercase italic grey wordmark 'theranos' in dark grey (#6D6E71 approx.) and the tagline 'redefining healthcare' in small grey monospaced-style letters beneath it. No photographs, charts, or other graphics.
Slide 7
2010 Goals Recap
Products:
• Launch Theranos Systems 4.0
• Establish volume capacity for millions of tests/month
Commercial:
Cash, Contracts, Market Share from at least 3 of each of:
• Enterprise deals with pharmaceutical companies
• Retail pharmacy deals
• Provider/Health ministry deals
Organization:
• World class products, sales, legal, and finance teams
Theranos Confidential
5
Visuals: One logo at top left: the Theranos mark, a green diamond-like faceted emblem (four-point star with lighter green gradient facets) followed by the italic grey wordmark 'theranos' and the tagline 'redefining healthcare' in small grey italic lowercase beneath it. No photographs, charts, or diagrams.
Slide 8
theranos
redefining healthcare
Products
Device
• 3x & minilab
Cartridge
• Multiplexing 65+ assays
• On board sample collection and processing
Assays
• Aptamers
• 800+ test menu & TPS library
Software
• Decision Support & Services
• Enterprise Pharmaceutical Suite
• Retail Pharmacy Suite
• Provider Suite
Theranos Confidential
6
Visuals: One logo, top-left: the Theranos logo, a green faceted diamond with a white square-cross centre and a grey italic lowercase wordmark 'theranos' with the tagline 'redefining healthcare' in small grey letters beneath. It is a placed raster image of 232 by 63 pixels, not cropped, on a white ground. No charts, photographs, tables or diagrams.
Slide 9
theranos
redefining healthcare
System Integration of New Technologies
Centrifuge
Nucleic Acid Ampl.
Cytometry
Colorimetry
ELISA
Robotics & Machine Vision
Theranos Confidential
7
Visuals: Six photographs of laboratory instruments, each with a black-and-silver palette, shown in oval crops inside light green rounded rectangular panels with grey outlines. Top row, left to right: Centrifuge (a black circular centrifuge rotor with silver posts, a sample holder in the centre, and hex bolts on the base, shot close-up at a slight angle). Nucleic Acid Ampl. (a dark rectangular instrument block with a blue-lit channel on top, a white plastic sample block at left, a green circuit board and tubing, lit with blue light). Cytometry (a ring of white LEDs around a polished steel bowl, with a white plate carrying thin channels and small red-tinted dots in the centre). Bottom row, left to right: Colorimetry (a clear plastic pipette tip descending into a dark background, with a bright white light streak across the lower part). ELISA (a silver pipette tip above an aluminium plate beside a black instrument with a blue label, with other silver probes visible at the top). Robotics & Machine Vision (a black machine frame with threaded lead screws and steel guide rods on a grey background). Each photo is cropped to an oval and sits inside its green panel with the image edges overlapping the panel edges.
Slide 10
theranos / redefining healthcare / Diverse Data Acquisition Across Technologies / Centrifuge / Nucleic Acid Ampl. / Cytometry / Colorimetry / ELISA / Robotics & Machine Vision / Theranos Confidential / 8
Visuals: Six photographs in rounded green cards, plus one green block arrow on the centrifuge card. Centrifuge: two photographs of a clear glass blood tube with a black rubber cap side by side on a white background; the left tube is filled with dark red blood to its full height, and the right tube, after centrifugation, shows a pale yellow plasma layer on top of a dark red cell layer at the bottom; a dark green block arrow with black outline points from left to right between them. Nucleic Acid Amplification: a close-up, boxed, rounded-corner photo of a row of green-lit wells on a black background; four well rings are visible with bright green fluorescent liquid in the centres, lit evenly. Cytometry: an oval-cropped false-colour microscope image on a dark navy background with scattered cells in purple, magenta and orange with bright yellow-white highlights. Colorimetry: an oval-cropped photo of four pipette tips filled with violet-blue liquid on a white background, the liquid getting paler from left to right, with a partly visible fifth tip at the far right edge. ELISA: an oval-cropped photo on black of a vertical tube glowing bright blue with a cyan-white glow at its bottom. Robotics & Machine Vision: an oval-cropped grey-toned image of three pipette tips in a dark grey rack with cyan outlines, containing red liquid in the tips, with a translucent white horizontal band with dashed black edges crossing the upper part of the tips. No charts, tables, logos other than the theranos logo, or icons.
Slide 11
theranos / redefining healthcare / Assay Validation Across Technologies / Centrifuge / Nucleic Acid Ampl. / Cytometry / Count / Log10 (Fluorescence intensity) / Hematocrit, % reported / DNA (ug/ml) / Colorimetry / ELISA / Robotics & Machine Vision / Hematocrit, % target / Predicted Conc (g/dL) / RLU / Nominal Conc (g/dL) / Conc (ng/ml) / Theranos Confidential / 9
Visuals: Six technology panels. Centrifuge: scatter plot titled none, x-axis Hematocrit, % target 0 to 80, y-axis Hematocrit, % reported 0 to 80; blue points at about (0,0), (30,30-32), (50,50-51), (70,68-70); dashed black linear trendline labelled y = 0.9522x + 2.0536, R^2 = 0.9964. Nucleic Acid Ampl.: bar chart, y-axis DNA (ug/ml) 0 to 90 in steps of 10, bars alternating red and blue: Dengue 1 red about 3, Negative Control blue about 4, Dengue 2 red about 3, Negative Control blue about 4, Dengue 3 red about 80 (highlighted tallest), Negative Control blue about 2, Dengue 4 red about 3, Negative Control blue about 3; category labels rotated 45 degrees. Cytometry: pink histogram with two peaks, y-axis Count (no numeric labels visible), x-axis Log10 (Fluorescence intensity) with tick marks, bars in #E8308A-like pink with white outlines; the axis label overflows the card. Colorimetry: scatter of black open circles with fitted line, label y = 1 x + -0.0262 and R^2 = 0.998 (R^2 in red), y-axis Predicted Conc (g/dL), x-axis Nominal Conc (g/dL), no numeric tick labels visible, white plot box. ELISA: blue fitted curve with grey data points, vertical cyan line at about 0.5 and green lines at about 5.00 and 500.00; y-axis RLU with ticks 5000, 20000, 100000; x-axis ticks 0.50, 5.00, 50.00, 500.00 labelled Conc (ng/ml). Robotics & Machine Vision: dense noisy grey-green micro-array texture of horizontal streaks on a white-bordered image, no legend.
Slide 12
Products / Regulatory / FDA / non-significant risk, class I devices / 510(k)s for diagnostic and predictive tests and ultimately, all / chemistries / CMS / CLIA-certification / LDTs / Theranos Confidential / 10
Visuals: Logo only: the theranos corporate mark at top left, a green faceted diamond with a white cross-shaped centre beside the grey italic wordmark 'theranos' and the small grey tagline 'redefining healthcare' below it. No charts, photographs or diagrams.
Slide 13
Operations and Production / Implementation of fully automated lines with comprehensive vision / inspection systems / Alchemist / • Automation of development / CLIA organizations and certifications, GMP (Good Manufacturing / Practices) compliance, and ISO certifications for ongoing regulatory / submissions / Theranos Confidential / 11
Visuals: Visual elements: one logo only. The theranos logo at top-left, 232 by 63 pixels, shows a green faceted diamond mark with a white inner cross pattern, next to a grey italic 'theranos' wordmark and a small grey italic 'redefining healthcare' tagline beneath it. No charts, tables, photographs or diagrams.
Slide 14
Commercial
Theranos businesses:
1.Physician’s office
2.Retail Rx
3.Pharmaceutical
4.Department of Defense, Government
Theranos Confidential
12
Visuals: One logo at top left: the theranos logo, a green faceted diamond mark with lowercase grey italic wordmark 'theranos' and the tagline 'redefining healthcare' beneath it in small grey italic lettering. No photographs, charts, or other graphics.
Slide 15
theranos / redefining healthcare / 2011 Commercial Plan / Q1 / Prepare for retail and physician’s office pilot launch / Regulatory and operations infrastructure in place / Q2 / Initiate retail and physician’s office pilots / Resume pharmaceutical contracts around fully integrated / solution for development acceleration (physical / infrastructure , software decision support, real-time / chemistry) / Q3 / Begin retail and physician’s office rollout / Pharmaceutical deployments / Q4 / Scale rollouts and begin deployments with multiple retail / partners / Theranos Confidential / 13
Visuals: Logo: the theranos corporate logo at top left, consisting of a green faceted diamond mark (four-point diamond with white internal cross-cut lines and a green-to-white gradient) to the left of an italic grey lowercase wordmark 'theranos' with the grey tagline 'redefining healthcare' in small italic letters beneath it. The image is a raster placed at 232 by 63 pixels, not cropped, on white. No photographs, charts, tables or other graphics.
Slide 16
Theranos Confidential / 14 / Commercial: Retail Rx / Walgreens / • $100M inventory pre-purchase / Safeway & Safeway Network / • $55M inventory pre-purchase / • ~$70M inventory pre-purchase / Target, Rite Aid, CVS Minute Clinics, & Walmart
Visuals: One logo, the Theranos wordmark, at top left: a green faceted diamond icon with white cross-shaped highlights and an italic grey 'theranos' wordmark with the tagline 'redefining healthcare' beneath it in small grey type. No photographs, charts, or diagrams.
Slide 17
Commercial: TPS
GSK
Celgene
Centocor
Sanofi-aventis
Astrazeneca
Retail pharmacy contracts with pharmaceutical partners
Theranos Confidential
15
Visuals: Theranos logo at upper left: a green faceted diamond-shaped mark (four-part rhombus with lighter highlights) followed by the lowercase italic grey wordmark 'theranos' and the smaller green-grey tagline 'redefining healthcare' beneath it. No other photographs, charts, or diagrams.
Slide 18
Commercial: Providers / BlueCross BlueShield Association and plans / United / Aetna, Cigna / DoD / IMSS, Pemex / Theranos Confidential / 16
Visuals: Logo: Theranos logo (green faceted diamond mark with italic grey wordmark 'theranos' and the tagline 'redefining healthcare' beneath), placed top-left at x 2.7%, y 3.5%, w 24.2%, h 8.8%, shown as a 232 by 63 pixel raster image with no border or frame. No charts, tables, photographs or other illustrations.
Slide 19
Organization / Our People: Building a World-Class Organization / Re-structured entire organization for scalability and rapid development cycles in preparation for retail launches / 13 team leads in place company wide around which all product and project teams are structured (from development to finance) / Team lead profile: BS, MS from MIT/Stanford, 2-10 years experience / Hiring to continually double headcount (150 people by 3/31/11) / Theranos Confidential / 17
Visuals: One visual element: the Theranos logo at top left (x 2.7%, y 3.5%, 24.2% by 8.8%, placed as a 232 by 63 pixel image). It has a green faceted diamond mark with white inner facets and a shaded green gradient, followed by the grey italic wordmark 'theranos' in a mid-grey (about #5F6368), and the small grey tagline 'redefining healthcare' in a lowercase sans-serif beneath it. No charts, photographs or other graphics appear on the slide.
Slide 20
theranos / redefining healthcare / Legal / Update on Government and Regulatory Affairs / Global Manufacturing Subsidiary & US Production / Intellectual Property & Trademarks / Theranos Confidential / 18
Visuals: Logo: the Theranos logo, a green faceted diamond mark with a white inner cross-like shape, to the right of which is the grey italic lowercase wordmark 'theranos' with the tagline 'redefining healthcare' in small grey italic lowercase beneath it. Bounding box x 2.7%, y 3.5%, w 24.2%, h 8.8% (232 by 63 pixels). No other visuals.
Slide 21
theranos
redefining healthcare
Theranos Intellectual Property Portfolio
Code
Patent Family
Status
Value
704
Pill & patch
Patch issued with narrow claims, other claims still being pursued
Publication blocks other companies from patents
707
Communications
US patent issued; foreign equivalents beginning to issue
Blocking for distributed test systems with wireless communication
711
Calibration
US claims allowed
Protects/blocks on-board calibrators used to update factory calibration
713
Detection of Influenza virus infection
Published, pending
Would protect ideas for assay configurations
725
Multivariate methods
Published, pending
Would protect use of multianalyte trend analysis in disease and therapy management
727
Modular POC systems
Published, pending
Would protect existing immunoassay system (pipette + tips)
732
Integrated health data capture and analysis
PCT filed
Would protect "Theranos Health Shield".; monitor and control ID outbreaks
733
Systems for sample use maximization
In preparation
Would protect the 4.0 System (Image analysis, protocol management, use of centrifuge)
Theranos Confidential
19
Visuals: Logo: raster image (232 by 63 pixels) at top left showing a green faceted diamond-like mark with a grey italic wordmark 'theranos' and small green tagline 'redefining healthcare' beneath. Table: 4 columns and 8 body rows plus header. Header row: Code | Patent Family | Status | Value, white bold text on light green #8AE28C. Row 1: 704 | Pill & patch | Patch issued with narrow claims, other claims still being pursued | Publication blocks other companies from patents. Row 2: 707 | Communications | US patent issued; foreign equivalents beginning to issue | Blocking for distributed test systems with wireless communication. Row 3: 711 | Calibration | US claims allowed | Protects/blocks on-board calibrators used to update factory calibration. Row 4: 713 | Detection of Influenza virus infection | Published, pending | Would protect ideas for assay configurations. Row 5: 725 | Multivariate methods | Published, pending | Would protect use of multianalyte trend analysis in disease and therapy management. Row 6: 727 | Modular POC systems | Published, pending | Would protect existing immunoassay system (pipette + tips). Row 7: 732 | Integrated health data capture and analysis | PCT filed | Would protect "Theranos Health Shield".; monitor and control ID outbreaks. Row 8: 733 | Systems for sample use maximization | In preparation | Would protect the 4.0 System (Image analysis, protocol management, use of centrifuge). Body rows alternate pale teal #E7F3F4 and near-white #F3F9FA. No photographs, charts or icons.
Slide 22
theranos redefining healthcare / Finance / Real Estate Update / Palo Alto: Additional facilities / • 3172 Porter at $2.05 NNN (55k sf) staged lease / • BSL 2/3 labs / • 3201 Hillview / - Utah / Approval of Real Estate Committee / C-2 Financing / Preferred Shares & Share Repurchase / Projected Financial Statements / Theranos Confidential / 20
Visuals: Non-text visuals: one logo image at x 2.7%, y 3.5%, w 24.2%, h 8.8% (232 by 63 pixels). It shows a green faceted diamond-shaped emblem with a white four-point star cut-out in its centre, followed by the italic grey wordmark 'theranos' and the small grey italic line 'redefining healthcare' beneath it. Colours are green gradient (#008851 range, lighter toward the centre) and mid-grey wordmark. No photographs, charts, tables or diagrams. The green footer band is a solid filled rectangle.